From January 5 to 8, 2023, the national medical insurance negotiations were successfully held, and on the night of the 8th, the National Health Insurance Administration released news that the negotiations on azvudine tablets and lung cleansing and detoxification granules were successful, while Paxlovid failed to negotiate due to the high quotation of the manufacturer Pfizer
.
Paxlovid failed negotiations due to high offers
According to public information, Paxlovid was conditionally approved by the State Food and Drug Administration on February 1, 2022 and was temporarily included in medical insurance, and the current medical insurance payment price has been reduced from the previous 2300 yuan / box to 1890 yuan / box
.
Beijing, Shanghai and other places have also included Paxlovid in temporary medical insurance
.
Although Paxlovid was unsuccessful in the national medical insurance negotiations, according to the relevant notices and related diagnosis and treatment methods jointly issued by the National Health Insurance Administration and relevant departments, including Paxlovid, azvudine tablets, monoravir capsules, cold and wet granules, etc.
, medical insurance will be temporarily paid until March 31
, 2023.
It is worth mentioning that with the advancement of drug regulatory authorities and the acceleration of new drug research and development, the speed of drug listing is also accelerating
.
In addition to Paxlovid, which has attracted much attention in the industry, in December 2022, the State Food and Drug Administration conditionally approved the import registration
of Monoravir capsules from Merck.
In addition to multinational pharmaceutical companies, domestic pharmaceutical companies are also making efforts, among which Azvudine tablets have been approved for marketing in China, in addition, Junshi Biologics' VV116, Ascletis Pharmaceutical's polymerase inhibitor ASC10, and CSPC's SYH2055 have all entered clinical trials
.
In this regard, the industry believes that as the launch of related drugs accelerates, Paxlovid's future pricing may also be under pressure
.
Anticancer drugs and rare disease drugs are the focus of this round of negotiations
According to the list previously released by the National Health Insurance Administration, 343 drugs passed the formal review this time, including 198 new varieties of drugs outside the list and 145 varieties of drugs renewed in the catalog
.
The drugs participating in this year's national medical insurance negotiations are not lacking CAR-T drugs, PD-1/PD-L1 anti-tumor drugs, high-value rare disease drugs and other drugs that have attracted much attention in the industry
.
Anticancer drugs and rare disease drugs are the focus of
this round of negotiations.
It is reported that in this medical insurance negotiation, in addition to multinational pharmaceutical companies, including Bayer Pharmaceutical, BAHEAL Pharmaceutical, Xi'an Janssen, Yangtze River Pharmaceutical, Hairong Pharmaceutical, Jichuan Pharmaceutical, BeiGene, Simcere Pharmaceutical, Junshi Biologics and other domestic pharmaceutical companies have anticancer drugs whose products have passed the preliminary form review, as well as some high-value drugs
for rare diseases.
Among them, 6 PD-1 anti-tumor drugs participated in the negotiation, including Hengrui Pharmaceutical's carrelizumab for injection, Junshi Biologics' teripulimab, BeiGene's tirelizumab, and Innovent Biologics' sindilimab, which have previously entered the medical insurance catalog, and will negotiate new indications
this time.
In addition, Henlius and Corning Jerry/Sidi / Simcere Pharmaceutical, two newly approved PD-1/PD-L1 models participated in this round of negotiations
.
Previously, Deppon Securities said in a research report that with the subsequent inclusion of 4 domestic PD-1 monoclonal antibodies into medical insurance and product price reductions, domestic PD-1 will further expand its domestic market share
.
In addition, 19 rare disease drugs are participating in the negotiations, including drugs for the treatment of spinal muscular atrophy (SMA), Castleman's disease, Fabry's disease, Gaucher disease, multiple sclerosis and other rare diseases
.
In the 2021 medical insurance negotiations, Biogen's rare disease SMA treatment drug nocinaxen sodium injection was successfully reduced from 700,000 / needle to 33,000 / injection, which brought hope to the majority of rare disease patients.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
